Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast
The ovarian cancer treatment landscape has been transformed by the angiogenesis inhibitor bevacizumab and the poly ADP ribose polymerase (PARP) inhibitors Lynparza (AstraZeneca / Merck & Co.), Zejula (GlaxoSmithKline), and Rubraca (Clovis Oncology). In November 2022, Elahere (ImmunoGen) entered the U.S. market as the first antibody-drug conjugate for patients with folate receptor alpha (FRα)-positive tumors. The late-phase pipeline for ovarian cancer is rapidly evolving. Novel drugs with a variety of mechanisms of action are set to launch for ovarian cancer and further diversify treatment options.
Questions answered
- What is the size of the clinically and commercially relevant drug-treatable ovarian cancer population, and how will drug-treatment rates change over time?
- What is the current treatment landscape for ovarian cancer? What are interviewed experts’ insights on current therapies?
- What are the most promising agents in the late-phase pipeline, and how will they shape the future of the ovarian cancer market?
- What are the main drivers of and constraints in the treatment of ovarian cancer, and how will this market evolve over the forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Ovarian Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market share of drug classes for ovarian cancer: 2022
- Market share of drug classes for ovarian cancer: 2032
- Drug-treatable population share and major-market sales share in ovarian cancer: 2022
- Drug-treatable population share and major-market sales share in ovarian cancer: 2032
- Population positioning of therapies in ovarian cancer: United States
- Population positioning of therapies in ovarian cancer: Europe
- Population positioning of therapies in ovarian cancer: Japan
- Ovarian cancer SWOT analysis
- Market drivers and constraints
- What factors are driving the market for ovarian cancer?
- What factors are constraining the market for ovarian cancer?
- Major-market sales of ovarian cancer therapies by drug class: 2022-2032
- Major-market sales of targeted therapies for ovarian cancer: 2022-2032
- Major-market sales of PARP inhibitors by patient population: 2022-2032
- Segment-specific trends
- Key findings
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Medical practice
- Early-stage first-line ovarian cancer
- Advanced-stage first-line ovarian cancer
- Second- and third-line platinum-sensitive ovarian cancer
- Second- and third-line platinum-resistant and -refractory ovarian cancer
- Fourth- and subsequent-line ovarian cancer
- Country-specific ovarian cancer treatment guidelines
- Patient characteristics influencing drug selection in ovarian cancer
- Region-specific treatment
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for ovarian cancer
- Estimated market authorization dates of key emerging therapies for the treatment of ovarian cancer
- Immune checkpoint inhibitors
- Cancer vaccines
- Antiglucocorticoids
- CA-125-targeting agents
- Kinase inhibitors
- Recombinant fusion proteins
- Antibody-drug conjugates
- Bispecific antibodies
- Early-phase pipeline analysis
- Key findings
- Access and Reimbursement Overview
- Methodology
- Appendix
Marcos Fernández Alfara, M.Sc., Ph.D., Healthcare Research & Data Analyst, Oncology. Dr. Fernández has extensive experience in oncology, with a focus on novel immunotherapies for solid tumors. As part of his doctorate, he developed new strategies to boost immune responses against cancer cells. He obtained his master of science degree in cancer and stem cells from Utrecht University and his doctorate in biomedicine from the Institute for Research in Biomedicine at Barcelona University.
Charlotte Jago, Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Jago is a pharmaceutical industry analyst with more than 18 years’ experience, preceded by 5 years of laboratory research in academia (Imperial College London) and industry (Celltech, now UCB). She wrote the flagship Cortellis Drugs to Watch reports in 2013, 2014, 2015, and 2019 and led the improvement in immuno-oncology coverage on the Cortellis Competitive Intelligence platform. She holds a Ph.D. in immunology, a first-class degree in pharmacology, and a postgraduate certificate in journalism.